- High-risk HPV infection is independently, significantly associated with increased cardiovascular disease (CVD) events risk, especially among obese women with metabolic syndrome (MetS).
Why this matters
- Incorporate CVD prevention within management strategies in high-risk, young-to-middle-aged female HPV patients.
- Routinely screen obese HPV patients with MetS to reduce overall CVD risk, promote timely interventions.
- 63,411 participants, high-risk HPV prevalence was 7.6%.
- Rate of new-onset CVD: 1122 cases, 4.3/1000 person-years.
- Multivariate adjusted HR (aHR) for mediation by inflammation: 1.25 (95% CI, 1.03-1.52) for high-risk HPV-positive vs high-risk HPV-negative.
- Multivariate aHR in high-risk, HPV-positive, nonobese (1.13; 95% CI, 0.90-1.43) vs obese (1.71; 95% CI, 1.17-2.50), P=.02.
- Multivariate aHR for incident CVD in high-risk non-MetS (1.09; 95% CI, 0.87-1.36) vs MetS (1.99; 95% CI, 1.28-3.08), respectively, P=.05.
- Prospective cohort study evaluating the longitudinal effect of high-risk HPV on the development of CVD events, influence of obesity among young and middle-aged Korean adult women.
- Funding: National Research Foundation of Korea.
- Spontaneous HPV regression, incident cases not included.
- HPV testing bias.
- Specific HPV genotypes unexplored.